Recro Pharma Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Recro Pharma (REPH) Tops Q2 EPS by 29c, Revenues Beat; Raises FY19 Revenue Guidance
August 8, 2019 7:17 AM EDTRecro Pharma (NASDAQ: REPH) reported Q2 EPS of ($0.13), $0.29 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $31.26 million versus the consensus estimate of $23.59 million.
Our CDMO business has delivered record results, generating $56.3 million in year to date revenues, a 36% increase from the comparable six-month period in 2018, said Gerri Henwood, President and Chief Executive Officer of Recro Pharma. We are very pleased with the sales... More
